AccessHope’s Vice President, Value and Strategy and Medical Director, GI Oncology Dr. Afsaneh Barzi sat down with Alison Kanski at Precision Medicine Online to discuss the latest findings from a new pancreatic cancer study published in the Journal of Personalized Medicine that highlights AccessHope’s clinical impact on cases of pancreatic adenocarcinoma. Dr. Barzi outlines the molecular testing gaps in pancreatic cancer care and explains how AccessHope’s collaboration with NCI-Designated Comprehensive Cancer Centers can offer expertise designed to optimize care delivery in 94% of the cases.
Read the highlights on AccessHope’s blog
Subscribers of Precision Medicine Online can access the article here
